Titan Pharmaceuticals Inc
TTNPDelisted Oct 2, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000910267
Titan Pharmaceuticals Inc was delisted on Oct 2, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 18 institutions reported holding it in 13F filings for Q3 2025, worth $107.1K in total; no superinvestor held it.
13F holders, Q1 2024
Institutional positions in Titan Pharmaceuticals Inc as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- −7 vs. Q4 2023
- Shares held
- 32.1K
- −974.6K (−96.8%) vs. Q4 2023
- Total value
- $230.0K
- −$178.2K (−43.7%) vs. Q4 2023
- New holders
- 4
- 0 more added
- Sold out
- 11
- 11 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TTNP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 5 | $69 |
| Q1 2026 | 6 | $130 |
| Q4 2025 | 4 | $154 |
| Q3 2025 | 18 | $107.1K |
| Q2 2025 | 20 | $158.3K |
| Q1 2025 | 17 | $51.9K |
| Q4 2024 | 15 | $9.41K |
| Q3 2024 | 16 | $88.5K |
| Q2 2024 | 18 | $179.3K |
| Q1 2024 | 17 | $230.0K |
| Q4 2023 | 24 | $408.2K |
| Q3 2023 | 27 | $497.8K |
| Q2 2023 | 25 | $632.7K |
| Q1 2023 | 22 | $787.4K |
| Q4 2022 | 23 | $757.9K |
| Q3 2022 | 21 | $1.14M |
| Q2 2022 | 24 | $371.0K |
| Q1 2022 | 24 | $1.24M |
| Q4 2021 | 24 | $430.0K |
| Q3 2021 | 22 | $722.0K |
| Q2 2021 | 23 | $1.51M |
| Q1 2021 | 24 | $988.1K |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Titan Pharmaceuticals Inc; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Truist Financial Corp | 31,255 | $223.8K | 0.00% | −593,834−95.0% | Reduced |
| Tower Research Capital LLC (TRC) | 647 | $4.63K | 0.00% | −897−58.1% | Reduced |
| MCF Advisors LLC | 165 | $1.18K | 0.00% | +165 | New |
| Group One Trading, L.P. | 12 | $86 | 0.00% | −218−94.8% | Reduced |
| Bank of America Corp | 12 | $86 | 0.00% | −195−94.2% | Reduced |
| Advisor Group Holdings, Inc. | 10 | $70 | 0.00% | −27−73.0% | Reduced |
| Wells Fargo & Company | 5 | $36 | 0.00% | −84−94.4% | Reduced |
| Morgan Stanley | 3 | $21 | 0.00% | 00.0% | Unchanged |
| Global Wealth Strategies & Associates | 2 | $14 | 0.00% | −38−95.0% | Reduced |
| Nemes Rush Group LLC | 1 | $8 | 0.00% | +1 | New |
| Westside Investment Management, Inc. | 1 | $7 | 0.00% | −3−75.0% | Reduced |
| GWM Advisors LLC | 1 | $7 | 0.00% | −3−75.0% | Reduced |
| Caldwell Sutter Capital, Inc. | 1 | $7 | 0.00% | −1−50.0% | Reduced |
| UBS Group AG | 1 | $7 | 0.00% | −1−50.0% | Reduced |
| St Germain D J Co Inc | 1 | $7 | 0.00% | 00.0% | Unchanged |
| Cape Investment Advisory, Inc. | 1 | $7 | 0.00% | +1 | New |
| Ransom Advisory, Ltd | 1 | $7 | 0.00% | +1 | New |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −135,310−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −82,051−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −87,945−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −38,287−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −19,596−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −15,113−100.0% | Sold out |
| Level Financial Advisors, Inc. | 0 | $0 | 0.00% | −987−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −154−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −60−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −2−100.0% | Sold out |